PSTX vs. CADL, GLUE, ADAP, IVVD, STRO, FENC, CHRS, AVXL, AGEN, and MGX
Should you be buying Poseida Therapeutics stock or one of its competitors? The main competitors of Poseida Therapeutics include Candel Therapeutics (CADL), Monte Rosa Therapeutics (GLUE), Adaptimmune Therapeutics (ADAP), Invivyd (IVVD), Sutro Biopharma (STRO), Fennec Pharmaceuticals (FENC), Coherus BioSciences (CHRS), Anavex Life Sciences (AVXL), Agenus (AGEN), and Metagenomi (MGX). These companies are all part of the "biological products, except diagnostic" industry.
Candel Therapeutics (NASDAQ:CADL) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.
In the previous week, Candel Therapeutics had 1 more articles in the media than Poseida Therapeutics. MarketBeat recorded 8 mentions for Candel Therapeutics and 7 mentions for Poseida Therapeutics. Poseida Therapeutics' average media sentiment score of 0.74 beat Candel Therapeutics' score of 0.65 indicating that Candel Therapeutics is being referred to more favorably in the media.
13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 46.9% of Poseida Therapeutics shares are held by institutional investors. 44.6% of Candel Therapeutics shares are held by company insiders. Comparatively, 2.1% of Poseida Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Candel Therapeutics has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500. Comparatively, Poseida Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
Candel Therapeutics has a net margin of 0.00% compared to Candel Therapeutics' net margin of -190.76%. Candel Therapeutics' return on equity of -94.90% beat Poseida Therapeutics' return on equity.
Poseida Therapeutics received 25 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 64.71% of users gave Poseida Therapeutics an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
Candel Therapeutics currently has a consensus target price of $11.00, suggesting a potential downside of 21.20%. Poseida Therapeutics has a consensus target price of $14.67, suggesting a potential upside of 323.89%. Given Candel Therapeutics' higher possible upside, analysts clearly believe Poseida Therapeutics is more favorable than Candel Therapeutics.
Candel Therapeutics has higher earnings, but lower revenue than Poseida Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Poseida Therapeutics beats Candel Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Poseida Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poseida Therapeutics Competitors List
Related Companies and Tools
